India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,673 Suresh G Kare ₹1,100 Cr
Market Cap
₹2,137 Cr
INDOCO · NSE
Share Price
₹228.90
-1.12% today
Revenue
₹1,845 Cr
FY 2025-26 · +10.8% YoY
EBITDA
₹135 Cr
Margin 7.3%
Net Profit
−₹91.69 Cr
FY 2025-26 · -22.4% YoY
ROE
-10.1%
ROCE 0.8%
Debt / Equity
1.06
Interest cover 1,364.4x
Authorised capital
₹25 Cr
Registered with MCA
About Indoco Remedies Limited
Data last updated:
Indoco Remedies Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 August 1947 and has been in existence for over 79 years.
Its director Suresh G Kare is #1,673 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L85190MH1947PLC005913. Its GSTIN is 27AAACI0380C1Z3 (Maharashtra). The company holds 28 GST registrations, of which 21 are active. Its shares are listed on BSE: 532612 and NSE: INDOCO.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹18.46 Cr. It is led by directors including Sundeep Vasant Bambolkar (Managing Director) and Aditi Milind Panandikar (Managing Director).
Its last annual general meeting (AGM) was held on 11 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Indoco House 166 Cst Roadvidyanagari Marg Kalina Santacruz East, Mumbai, Maharashtra, India – 400098.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,845.32 Cr, a growth of 10.8% compared to the previous year. For the same year it recorded a net loss of ₹91.69 Cr (net margin -5%) and EBITDA of ₹135.41 Cr (EBITDA margin 7.3%). The net worth stands at ₹939.28 Cr (down 8.1% YoY). Total assets are valued at ₹2,067.75 Cr (up 0.4% YoY).
The company has about 6,460 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 2 brands: AnaCipher CRO and Indoco Remedies. As per MCA filings, the company has open charges of ₹787.06 Cr and satisfied charges of ₹717.82 Cr on record. Court records list 224 cases involving the company, including 154 filed by the company and 71 filed against it; 47 cases are pending. The company has 31 deals on record (27 market trades, 3 secondary share transfers, 1 funding round), with disclosed funding of ₹46.5 Lakh; the latest was in June 2026. Its 10 peer companies in the Pharma industry (API Manufacturers, Contract Research, Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Sai Life Sciences Limited with revenue of ₹1,731.35 Cr. The company has 19 MSME Form 1 returns on record between 2016 and 2024, listing 86 overdue payments to 45 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indoco.com.
Company Details of Indoco Remedies Limited
CIN L85190MH1947PLC005913
Registration Number 005913
Incorporation Date 23 August 1947
ROC Mumbai
Listing Status Listed (BSE: 532612, NSE: INDOCO)
Company Status Active
Date of Last AGM 11 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
CIN History of Indoco Remedies Limited
Indoco Remedies has one previous CIN (Corporate Identification Number): U85190MH1947PTC005913. The current CIN is L85190MH1947PLC005913, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85190MH1947PLC005913 | Current |
| U85190MH1947PTC005913 | Previous |
Key People
Sundeep Vasant Bambolkar Managing Director Aditi Milind Panandikar Managing Director Suresh Govind Kare Director Recognitions & Rankings of Indoco Remedies
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressIndoco House 166 Cst Roadvidyanagari Marg Kalina Santacruz East, Mumbai, Maharashtra, India – 400098
- IndustryPharma, Drug Formulation & Development, API Manufacturers, Pharma Contract R&D
Comprehensive company report
Indoco Remedies Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Indoco Remedies Limited
Indoco Remedies operates two associated brands: AnaCipher CRO and Indoco Remedies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides clinical research and bioequivalence studies for pharmaceutical partners. | anaciphercro.com | |
| APIs manufacturing and formulation services are provided in therapeutic segments. | indoco.com |
Business Activity of Indoco Remedies Limited
The main business activity of Indoco Remedies is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Indoco Remedies Limited FY 2025-26 filings available
Indoco Remedies Limited reported revenue of ₹1,845.32 Cr (up 10.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹1,845 Cr
+10.8% YoY
EBITDA
₹135 Cr
+36.4% YoY
Profit After Tax
−₹91.69 Cr
-22.4% YoY
Net Worth
₹939 Cr
-8.1% YoY
Total Assets
₹2,068 Cr
+0.4% YoY
Total Debt
₹1,090 Cr
+9.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,845 | 1,665 | 1,817 | 1,669 | 1,541 | 1,242 | 1,107 |
| Revenue growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| EBITDA | 135 | 99.26 | 236 | 286 | 327 | 224 | 123 |
| EBITDA margin | +7.3% | +6.0% | +13.0% | +17.2% | +21.3% | +18.1% | +11.1% |
| Profit before tax | (106) | (74.36) | 136 | 193 | 237 | 132 | 28.57 |
| Net profit | (91.69) | (74.94) | 90.51 | 143 | 155 | 93.23 | 24.30 |
| Net profit margin | -5.0% | -4.5% | +5.0% | +8.6% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Balance sheet | |||||||
| Total assets | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Net worth | 939 | 1,022 | 1,110 | 1,028 | 905 | 769 | 680 |
| Total debt | 1,090 | 994 | 672 | 333 | 257 | 267 | 262 |
| Cash & bank | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Net working capital | 672 | 644 | 643 | 562 | 499 | 378 | 269 |
| Cash flow | |||||||
| Cash from operations | 192 | 94.94 | 157 | 179 | 174 | 82.22 | 123 |
| Cash from investing | (102) | (339) | (433) | (208) | (121) | (66.69) | (55.93) |
| Cash from financing | (76.79) | 241 | 280 | 22.80 | (44.37) | (29.87) | (63.95) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 468 | 476 | 445 | 485 | 440 | 390 | 411 | 433 |
| Revenue growth (YoY) | +6.3% | +21.9% | +8.5% | +12.0% | +1.9% | - | - | - |
| Other income | 99.52 | 3.70 | 0.98 | 0.76 | 1.63 | 2.02 | 1.84 | 1.56 |
| EBITDA | 41.02 | 49.71 | 25.36 | 42.52 | 17.53 | (0.78) | 12.03 | 40.25 |
| EBITDA margin | +8.8% | +10.9% | +5.8% | +9.0% | +4.1% | -0.2% | +3.0% | +9.3% |
| Depreciation | 34.53 | 32.49 | 32.01 | 32.25 | 29.70 | 28.78 | 28.72 | 28.82 |
| Interest | 28.29 | 45.92 | 25.64 | 24.56 | 26.12 | 17.98 | 16.11 | 17.83 |
| Profit before tax | 77.72 | (25.00) | (31.31) | (13.53) | (36.66) | (45.52) | (30.96) | (4.84) |
| Tax | 12.28 | (1.32) | (1.86) | (4.32) | (0.31) | (4.18) | (2.56) | 5.17 |
| Net profit | 65.44 | (23.68) | (29.45) | (9.21) | (36.35) | (41.34) | (28.40) | (10.01) |
| EPS (₹) | 7.09 | (2.56) | (3.19) | (1.00) | (3.94) | (4.48) | (3.08) | (1.08) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,686 | 1,518 | 1,791 | 1,667 | 1,540 | 1,240 | 1,106 |
| Revenue growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| EBITDA | 151 | 128 | 250 | 285 | 327 | 224 | 123 |
| EBITDA margin | +9.0% | +8.4% | +14.0% | +17.1% | +21.2% | +18.0% | +11.2% |
| Profit before tax | (11.46) | (7.36) | 153 | 192 | 236 | 131 | 28.70 |
| Net profit | (3.07) | (10.08) | 108 | 142 | 155 | 92.56 | 24.43 |
| Net profit margin | -0.2% | -0.7% | +6.0% | +8.5% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Balance sheet | |||||||
| Total assets | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Net worth | 1,099 | 1,103 | 1,127 | 1,027 | 904 | 769 | 680 |
| Total debt | 760 | 754 | 514 | 333 | 257 | 258 | 262 |
| Cash & bank | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Net working capital | 654 | 651 | 628 | 559 | 496 | 375 | 267 |
| Cash flow | |||||||
| Cash from operations | 226 | 107 | 177 | 179 | 174 | 82.17 | 123 |
| Cash from investing | (87.38) | (276) | (302) | (209) | (121) | (66.70) | (55.95) |
| Cash from financing | (133) | 169 | 122 | 22.81 | (44.37) | (29.83) | (63.95) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 409 | 449 | 401 | 442 | 394 | 347 | 373 | 397 |
| Revenue growth (YoY) | +3.7% | +29.3% | +7.4% | +11.5% | -1.8% | - | - | - |
| Other income | 102 | 14.03 | 7.17 | 6.54 | 5.58 | 6.50 | 5.25 | 4.20 |
| Total expenses | 367 | 386 | 381 | 389 | 379 | 344 | 353 | 344 |
| EBITDA | 42.21 | 63.03 | 19.89 | 52.86 | 14.82 | 3.46 | 20.14 | 52.87 |
| EBITDA margin | +10.3% | +14.7% | +5.1% | +12.3% | +3.8% | +1.0% | +5.5% | +13.4% |
| Depreciation | 28.05 | 26.71 | 27.36 | 27.63 | 25.20 | 24.88 | 24.75 | 24.92 |
| Interest | 22.75 | 22.73 | 20.15 | 22.01 | 23.61 | 15.98 | 14.00 | 14.77 |
| Profit before tax | 93.22 | 27.62 | (20.45) | 9.76 | (28.41) | (30.90) | (13.36) | 17.38 |
| Tax | 10.90 | 0.27 | (0.45) | (5.29) | (0.34) | (4.66) | (3.13) | 4.59 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 468 | 476 | 445 | 485 | 440 | 390 | 411 | 433 |
| Revenue growth (YoY) | +6.3% | +21.9% | +8.5% | +12.0% | +1.9% | - | - | - |
| Other income | 99.52 | 3.70 | 0.98 | 0.76 | 1.63 | 2.02 | 1.84 | 1.56 |
| EBITDA | 41.02 | 49.71 | 25.36 | 42.52 | 17.53 | (0.78) | 12.03 | 40.25 |
| EBITDA margin | +8.8% | +10.9% | +5.8% | +9.0% | +4.1% | -0.2% | +3.0% | +9.3% |
| Depreciation | 34.53 | 32.49 | 32.01 | 32.25 | 29.70 | 28.78 | 28.72 | 28.82 |
| Interest | 28.29 | 45.92 | 25.64 | 24.56 | 26.12 | 17.98 | 16.11 | 17.83 |
| Profit before tax | 77.72 | (25.00) | (31.31) | (13.53) | (36.66) | (45.52) | (30.96) | (4.84) |
| Tax | 12.28 | (1.32) | (1.86) | (4.32) | (0.31) | (4.18) | (2.56) | 5.17 |
| Net profit | 65.44 | (23.68) | (29.45) | (9.21) | (36.35) | (41.34) | (28.40) | (10.01) |
| EPS (₹) | 7.09 | (2.56) | (3.19) | (1.00) | (3.94) | (4.48) | (3.08) | (1.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,845 | 1,665 | 1,817 | 1,669 | 1,541 | 1,242 | 1,107 |
| Revenue growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| Other income | 6.79 | 6.45 | 29.58 | 2.34 | 2.33 | 3.12 | 2.44 |
| Total expenses | 1,710 | 1,566 | 1,581 | 1,383 | 1,213 | 1,017 | 983 |
| Employee cost | 426 | 394 | 362 | 323 | 296 | 274 | 257 |
| EBITDA | 135 | 99.26 | 236 | 286 | 327 | 224 | 123 |
| EBITDA margin | +7.3% | +6.0% | +13.0% | +17.2% | +21.3% | +18.1% | +11.1% |
| Depreciation | 126 | 114 | 91.87 | 70.61 | 78.96 | 73.13 | 70.82 |
| Interest | 122 | 66.23 | 38.02 | 25.03 | 14.14 | 22.26 | 26.25 |
| Profit before tax | (106) | (74.36) | 136 | 193 | 237 | 132 | 28.57 |
| Tax | (7.81) | 3.58 | 38.79 | 50.55 | 81.77 | 38.95 | 4.46 |
| Net profit | (91.69) | (74.94) | 90.51 | 143 | 155 | 93.23 | 24.30 |
| Net profit margin | -5.0% | -4.5% | +5.0% | +8.6% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 18.46 | 18.45 | 18.44 | 18.43 | 18.43 | 18.43 | 18.43 |
| Reserves & surplus | 921 | 1,004 | 1,091 | 1,010 | 886 | 751 | 661 |
| Shareholders' funds (net worth) | 939 | 1,022 | 1,110 | 1,028 | 905 | 769 | 680 |
| Minority interest | (7.17) | (3.62) | 0.60 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 866 | 785 | 498 | 267 | 177 | 176 | 194 |
| Unsecured loans | 224 | 208 | 174 | 66.14 | 79.87 | 90.99 | 67.54 |
| Total debt | 1,090 | 994 | 672 | 333 | 257 | 267 | 262 |
| Total liabilities | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Assets | |||||||
| Gross block | 2,232 | 1,928 | 1,781 | 1,423 | 1,236 | 1,178 | 1,127 |
| Net block | 1,193 | 997 | 954 | 678 | 555 | 570 | 590 |
| Capital work in progress | 90.01 | 321 | 125 | 114 | 122 | 68.10 | 50.70 |
| Investments | 1.46 | 1.46 | 8.71 | 2.46 | 0.02 | 0.02 | 0.02 |
| Inventories | 405 | 419 | 353 | 326 | 311 | 238 | 208 |
| Sundry debtors | 489 | 352 | 406 | 351 | 297 | 234 | 210 |
| Cash & bank balances | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Loans & advances | 266 | 212 | 164 | 122 | 146 | 137 | 107 |
| Total current assets | 1,193 | 1,001 | 947 | 813 | 774 | 623 | 563 |
| Total current liabilities | 521 | 357 | 305 | 250 | 275 | 244 | 294 |
| Net working capital | 672 | 644 | 643 | 562 | 499 | 378 | 269 |
| Total assets | 2,068 | 2,060 | 1,828 | 1,402 | 1,200 | 1,071 | 977 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.11 | 14.86 | 10.92 | 17.47 | 9.42 | 23.76 | 20.80 |
| Net cash from operating activities | 192 | 94.94 | 157 | 179 | 174 | 82.22 | 123 |
| Net cash from investing activities | (102) | (339) | (433) | (208) | (121) | (66.69) | (55.93) |
| Net cash from financing activities | (76.79) | 241 | 280 | 22.80 | (44.37) | (29.87) | (63.95) |
| Net change in cash | 13.82 | (2.75) | 3.93 | (6.54) | 8.05 | (14.34) | 2.97 |
| Closing cash | 32.99 | 17.08 | 24.32 | 13.34 | 19.77 | 14.34 | 37.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.8% | -8.4% | +8.9% | +8.3% | +24.1% | +12.2% | - |
| EBITDA growth | +36.4% | -58.0% | -17.5% | -12.6% | +46.0% | +82.1% | - |
| PBT growth | -43.2% | - | -29.6% | -18.5% | +79.2% | +362.1% | +9998.0% |
| Net income growth | -22.4% | -182.8% | -36.8% | -7.7% | +66.4% | +283.7% | - |
| Revenue CAGR (3Y) | +3.4% | +2.6% | +13.5% | +14.7% | +16.7% | +6.0% | +1.0% |
| EBITDA CAGR (3Y) | -22.1% | -32.8% | +1.7% | +32.4% | +62.3% | +18.5% | -7.7% |
| Profitability & leverage | |||||||
| Net income margin | -5.4% | -4.7% | +5.3% | +8.5% | +10.1% | +7.5% | +2.2% |
| Return on capital employed | +0.8% | -0.4% | +10.8% | +16.7% | +22.1% | +15.1% | +5.6% |
| Return on net worth | -10.1% | -7.3% | +9.1% | +14.7% | +18.5% | +12.9% | +3.6% |
| Debt / equity | 1.06 | 0.78 | 0.47 | 0.30 | 0.31 | 0.36 | 0.42 |
| Long-term debt / equity | 0.63 | 0.48 | 0.28 | 0.16 | 0.13 | 0.14 | 0.17 |
| Interest cover | 1,364.40 | -454.25 | 26.36 | 11.62 | 5.69 | 14.73 | 50.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.89 | 0.90 | 1.13 | 1.26 | 1.28 | 1.08 | 1.07 |
| Inventory turnover | 4.48 | 4.31 | 5.35 | 5.24 | 5.62 | 5.57 | 5.65 |
| Debtors turnover | 4.39 | 4.39 | 4.80 | 5.15 | 5.80 | 5.59 | 5.45 |
| EPS (₹) | (10.31) | (7.99) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
| Dividend per share (₹) | 0.20 | 0.20 | 1.50 | 2.25 | 2.25 | 1.50 | 0.30 |
| Book value per share (₹) | 101.76 | 110.79 | 120.40 | 111.58 | 98.17 | 83.45 | 73.75 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 409 | 449 | 401 | 442 | 394 | 347 | 373 | 397 |
| Revenue growth (YoY) | +3.7% | +29.3% | +7.4% | +11.5% | -1.8% | - | - | - |
| Other income | 102 | 14.03 | 7.17 | 6.54 | 5.58 | 6.50 | 5.25 | 4.20 |
| Total expenses | 367 | 386 | 381 | 389 | 379 | 344 | 353 | 344 |
| EBITDA | 42.21 | 63.03 | 19.89 | 52.86 | 14.82 | 3.46 | 20.14 | 52.87 |
| EBITDA margin | +10.3% | +14.7% | +5.1% | +12.3% | +3.8% | +1.0% | +5.5% | +13.4% |
| Depreciation | 28.05 | 26.71 | 27.36 | 27.63 | 25.20 | 24.88 | 24.75 | 24.92 |
| Interest | 22.75 | 22.73 | 20.15 | 22.01 | 23.61 | 15.98 | 14.00 | 14.77 |
| Profit before tax | 93.22 | 27.62 | (20.45) | 9.76 | (28.41) | (30.90) | (13.36) | 17.38 |
| Tax | 10.90 | 0.27 | (0.45) | (5.29) | (0.34) | (4.66) | (3.13) | 4.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,686 | 1,518 | 1,791 | 1,667 | 1,540 | 1,240 | 1,106 |
| Revenue growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| Other income | 33.10 | 19.48 | 28.24 | 2.33 | 2.32 | 3.11 | 2.43 |
| Total expenses | 1,535 | 1,390 | 1,541 | 1,382 | 1,213 | 1,017 | 983 |
| Employee cost | 394 | 369 | 351 | 321 | 295 | 273 | 255 |
| EBITDA | 151 | 128 | 250 | 285 | 327 | 224 | 123 |
| EBITDA margin | +9.0% | +8.4% | +14.0% | +17.1% | +21.2% | +18.0% | +11.2% |
| Depreciation | 107 | 98.25 | 87.98 | 70.60 | 78.95 | 73.12 | 70.81 |
| Interest | 88.50 | 56.63 | 36.81 | 25.03 | 14.14 | 22.22 | 26.25 |
| Profit before tax | (11.46) | (7.36) | 153 | 192 | 236 | 131 | 28.70 |
| Tax | (5.81) | 1.36 | 36.58 | 50.23 | 81.71 | 38.95 | 4.46 |
| Net profit | (3.07) | (10.08) | 108 | 142 | 155 | 92.56 | 24.43 |
| Net profit margin | -0.2% | -0.7% | +6.0% | +8.5% | +10.1% | +7.5% | +2.2% |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 18.46 | 18.45 | 18.44 | 18.43 | 18.43 | 18.43 | 18.43 |
| Reserves & surplus | 1,081 | 1,085 | 1,108 | 1,009 | 886 | 750 | 662 |
| Shareholders' funds (net worth) | 1,099 | 1,103 | 1,127 | 1,027 | 904 | 769 | 680 |
| Secured loans | 522 | 508 | 328 | 267 | 177 | 165 | 184 |
| Unsecured loans | 238 | 246 | 186 | 66.14 | 79.87 | 93.44 | 77.54 |
| Total debt | 760 | 754 | 514 | 333 | 257 | 258 | 262 |
| Total liabilities | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Assets | |||||||
| Gross block | 1,851 | 1,666 | 1,555 | 1,406 | 1,236 | 1,178 | 1,127 |
| Net block | 851 | 754 | 732 | 661 | 555 | 570 | 590 |
| Capital work in progress | 85.21 | 226 | 114 | 113 | 122 | 68.10 | 50.70 |
| Investments | 160 | 51.96 | 59.20 | 19.90 | 2.46 | 2.45 | 2.45 |
| Inventories | 322 | 363 | 310 | 326 | 311 | 238 | 208 |
| Sundry debtors | 541 | 374 | 408 | 351 | 297 | 234 | 209 |
| Cash & bank balances | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Loans & advances | 231 | 190 | 158 | 122 | 146 | 136 | 107 |
| Total current assets | 1,114 | 939 | 893 | 811 | 773 | 622 | 562 |
| Total current liabilities | 460 | 288 | 265 | 253 | 277 | 247 | 294 |
| Net working capital | 654 | 651 | 628 | 559 | 496 | 375 | 267 |
| Total assets | 1,904 | 1,904 | 1,686 | 1,401 | 1,200 | 1,069 | 978 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 7.06 | 7.47 | 9.99 | 16.90 | 9.13 | 23.48 | 20.72 |
| Net cash from operating activities | 226 | 107 | 177 | 179 | 174 | 82.17 | 123 |
| Net cash from investing activities | (87.38) | (276) | (302) | (209) | (121) | (66.70) | (55.95) |
| Net cash from financing activities | (133) | 169 | 122 | 22.81 | (44.37) | (29.83) | (63.95) |
| Net change in cash | 5.87 | (0.41) | (2.52) | (6.91) | 7.77 | (14.35) | 2.76 |
| Closing cash | 20.00 | 12.03 | 16.94 | 12.40 | 19.21 | 14.05 | 37.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +11.1% | -15.2% | +7.5% | +8.3% | +24.1% | +12.1% | - |
| EBITDA growth | +17.8% | -48.7% | -12.3% | -12.9% | +46.3% | +81.3% | - |
| PBT growth | -55.7% | - | -20.0% | -18.9% | +79.9% | +357.6% | +9998.0% |
| Net income growth | +69.5% | -109.3% | -24.0% | -8.1% | +67.3% | +278.9% | - |
| Revenue CAGR (3Y) | +0.4% | -0.5% | +13.0% | +14.7% | +16.7% | +6.1% | +1.0% |
| EBITDA CAGR (3Y) | -19.1% | -26.8% | +3.8% | +32.2% | +62.1% | +18.4% | -7.7% |
| Profitability & leverage | |||||||
| Net income margin | -0.3% | -0.6% | +6.5% | +8.5% | +10.0% | +7.5% | +2.2% |
| Return on capital employed | +4.2% | +2.7% | +12.3% | +16.7% | +22.1% | +15.0% | +5.6% |
| Return on net worth | -0.3% | -0.9% | +10.8% | +14.6% | +18.5% | +12.8% | +3.6% |
| Debt / equity | 0.69 | 0.57 | 0.39 | 0.31 | 0.31 | 0.36 | 0.42 |
| Long-term debt / equity | 0.31 | 0.25 | 0.19 | 0.14 | 0.12 | 0.13 | 0.17 |
| Interest cover | 201.41 | 190.10 | 22.75 | 11.68 | 5.70 | 14.77 | 49.98 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.96 | 0.94 | 1.21 | 1.26 | 1.28 | 1.08 | 1.07 |
| Inventory turnover | 4.93 | 4.51 | 5.63 | 5.24 | 5.62 | 5.56 | 5.65 |
| Debtors turnover | 3.68 | 3.88 | 4.72 | 5.15 | 5.80 | 5.60 | 5.48 |
| EPS (₹) | (0.61) | (0.95) | 12.65 | 15.34 | 16.77 | 10.03 | 2.63 |
| Dividend per share (₹) | 0.20 | 0.20 | 1.50 | 2.25 | 2.25 | 1.50 | 0.30 |
| Book value per share (₹) | 119.08 | 119.61 | 122.22 | 111.45 | 98.13 | 83.44 | 73.81 |
Want more history and ratios?
You're viewing the latest exchange-filed financials for Indoco Remedies Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board of Directors of Indoco Remedies Limited
Indoco Remedies has 7 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Suresh Govind Kare Also directs: Spa Holdings Private Limited, Warren Remedies Private Limited, Shanteri Investment Private Limited and 1 more | Director | 02 Jul 1963 | 63 Years 3 Months | Current |
| Sundeep Vasant Bambolkar | Managing Director | 27 Mar 2004 | 22 Years 6 Months | Current |
| Aditi Milind Panandikar | Managing Director | 27 Mar 2004 | 22 Years 6 Months | Current |
| Vasudha Vasant Kamat | Director | 27 Mar 2020 | 6 Years 6 Months | Current |
| Abhijit Yashawant Gore | Director | 03 Oct 2020 | 6 Years 0 Months | Current |
| Satish Madhav Shenoy Also directs: Paramount Speciality Forgings Limited, Kataline Limited | Director | 01 Apr 2024 | 2 Years 6 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer Comparison of Indoco Remedies Limited
Indoco Remedies Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Contract Research, Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Indoco Remedies Limited this company | ₹1,845.32 Cr (FY 2026) | •••• | •••• | 10.8% | •••• | Mumbai, Maharashtra, India |
| Sai Life Sciences Limited | ₹1,731.35 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Hyderabad, Telangana, India |
| Leeford Healthcare Limited | ₹1,730.47 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Ludhiana, Punjab, India |
| MSN Pharmachem Private Limited | ₹1,716.51 Cr (FY 2024) | •••• | •••• | 40.0% | •••• | Hyderabad, Telangana, India |
| Bharat Biotech International Limited | ₹1,699.59 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Hyderabad, Telangana, India |
| La Renon Healthcare Private Limited | ₹1,685.81 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Ahmedabad, Gujarat, India |
| Pure and Cure Healthcare Private Limited | ₹1,647.61 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Saraswati Vihar, Delhi, India |
| Dishman Pharmaceuticals and Chemicals Limited | ₹1,622.59 Cr (FY 2016) | •••• | •••• | -3.0% | •••• | Ahmedabad, Gujarat, India |
| Cipla Pharma and Life Sciences Limited | ₹1,598.45 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Mumbai, Maharashtra, India |
| Viyash Scientific Limited Listed | ₹1,566.06 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Hyderabad, Telangana, India |
| Impact Therapeutics Limited | ₹1,499.49 Cr (FY 2024) | •••• | •••• | 75.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Indoco Remedies by revenue in the Pharma industry (API Manufacturers, Contract Research, Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Indoco Remedies Limited
Indoco Remedies Limited is audited by Gokhale & Sathe for the financial year 2025.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Gokhale & Sathe | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Shareholding Pattern of Indoco Remedies Limited
Shareholding for the quarter ended Sep 2026: promoters hold 58.90%, foreign institutional investors hold 1.30%, domestic institutional investors hold 17.70% and retail and other public shareholders hold 22.10%.
Sep 2026
QUARTER
58.90% Promoters
17.70% DII (Domestic Institutional)
1.30% FII (Foreign Institutional)
22.10% Retail & Others
Promoter holding - history
Now 58.90% · Sep 2026High 58.90% · Dec 2025Low 58.90% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 58.90% | 58.90% | 58.90% | 58.90% |
| Public | 41.10% | 41.10% | 41.10% | 41.10% |
Charges & Borrowings of Indoco Remedies Limited
Open charges
₹787.06 Cr
Satisfied charges
₹717.82 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jun 2026 | Hdfc Bank Limited | ₹13 Cr | Open |
| 10 Jun 2026 | Others | ₹50 Cr | Open |
| 23 Mar 2026 | Others | ₹15 Cr | Open |
| 23 Mar 2026 | Others | ₹25 Cr | Open |
| 20 Apr 2025 | Hdfc Bank Limited | ₹244 Cr | Open |
Total charge records: 84 View all charges
Deals & Funding of Indoco Remedies Limited
Indoco Remedies Limited has 31 deals on record (27 market trades, 3 secondary share transfers, 1 funding round), with disclosed funding of ₹46.5 Lakh; the latest was in June 2026.
Total deals
31
Market trades
27
Secondary share transfers
3
Funding round
1
Disclosed funding
₹46.5 Lakh
Deals on record (5 of 31)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2026 | Market trade | ₹13.25 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
| May 2026 | Market trade | ₹13.35 Cr | Buyer: Icici Prudential Mutual Fund |
| May 2026 | Market trade | ₹13.53 Cr | Buyer: Icici Prudential Mutual Fund |
| Aug 2021 | Market trade | ₹24.5 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
| Mar 2009 | Market trade | ₹6.58 Cr | Buyer: Spa Holdings Private Limited Seller: Narsinh Investment And Fin Pvt Ltd |
Premium access
Full deal history
All 31 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Indoco Remedies Limited
Indoco Remedies Limited has 224 court cases on record: 154 filed by Indoco Remedies, 71 filed against it. 47 cases are pending and 177 are disposed.
Total cases
224
Filed by the company
154
Filed against the company
71
Pending
47
Disposed
177
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 117 | 36 | 31 |
| High courts | 103 | 32 | 16 |
| Supreme Court | 4 | 3 | 0 |
Cases on record (5 of 224)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Commercial suit | Filed against the company by Cedar Properties and Trading LLP & Ors. | Pending |
| Bombay High Court | Court case (CARAP) | Filed against the company by Sentiss Pharma Private Limited Through Its Authorised Signatory Ashish Lakhotia | Disposed |
| High Court | Court case (CARAP) | Filed against the company by Sentiss Pharma Private Limited | Disposed |
| High Court, MAHARASHTRA | Court case (CRR) | Filed by the company against Endoco Healthcare Private Limited and Ors | Disposed |
| High Court | Court case (COMIP) | Filed by the company against Endoco Healthcare Private Limited and 5 others | Disposed |
Premium access
Full case history
All 224 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Indoco Remedies Limited
Indoco Remedies Limited has 19 MSME Form 1 returns on record between 2016 and 2024, listing 86 overdue payments to 45 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 45)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Simplisol Technologies Private Limited | •••• | •••• | •••• |
| NDS Infotech Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 19 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Indoco Remedies Limited
Indoco Remedies Limited has a workforce of 6,460 employees as of Sep 24, 2025.
Employee count
6,460
Active EPFO establishments
7
Employee growth
2.25%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Indoco Remedies Limited
Indoco Remedies has 2 subsidiary companies and 2 associated companies. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.
2
Subsidiary companies
2
Associated companies
Key Subsidiaries
| Company Name | CIN | Shares Held |
|---|---|---|
| Warren Remedies Private Limited | U24304MH2022PTC384184 | - |
| Xtend Industrial Designers And Engineers Private Limited | U93000MH1995PTC086174 | - |
Showing major subsidiaries. Total: 2.
Recent Activity on Indoco Remedies Limited
Indoco Remedies Limited has 35 board changes on record since 1963: 22 appointments and 13 cessations. The latest: Ajay Prasan Mulgaokar was appointed as Director on 01 Apr 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 13.00 Cr with Charge ID 101317151 was registered on 29 Jun 2026.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101309850 was registered on 10 Jun 2026.
Charges
A charge with Others amounted to Rs. 15.00 Cr with Charge ID 101262410 was registered on 23 Mar 2026.
Charges
A charge with Others amounted to Rs. 25.00 Cr with Charge ID 101262453 was registered on 23 Mar 2026.
AGM
Indoco Remedies Limited last Annual general meeting of members was held on 11 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 244.00 Cr with Charge ID 101090244 was registered on 20 Apr 2025.
Filing
Indoco Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101059602 was registered on 27 Feb 2025.
Charges
A charge registered on 14 Dec 2017 via Charge ID 100141258 with Others was fully satisfied on 17 Feb 2025.
Charges
A charge registered on 20 Aug 2021 via Charge ID 100478315 with Others was fully satisfied on 12 Jul 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 42.00 Cr with Charge ID 100950241 was registered on 27 Jun 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 28.00 Cr with Charge ID 100937442 was registered on 30 May 2024.
189 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Indoco Remedies Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Indoco Remedies Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Indoco Remedies Limited
Indoco Remedies has 28 GST registrations: 21 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
28
Active
21
Cancelled / inactive
7
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACI0380C1Z3 | Maharashtra | Active | 01 Jul 2017 |
| 27AAACI0380C2Z2 | Maharashtra | Active | 07 Sep 2017 |
| 02AAACI0380C1ZF | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACI0380C1ZD | Punjab | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Indoco Remedies Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Indoco Remedies Limited
Indoco Remedies: Launches Fully-Owned Subsidiary Warren Lifesciences For Pharma Production
Frequently Asked Questions about Indoco Remedies Limited
Indoco Remedies is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 August 1947 (79+ years old) and is registered under CIN L85190MH1947PLC005913. Listed on BSE: 532612 and NSE: INDOCO.
Indoco Remedies reported revenue of ₹1,845.32 Cr for FY 2025-26 (up 10.8% YoY) based on consolidated financials.
Indoco Remedies has 7 current directors:
- Sundeep Vasant Bambolkar - Managing Director
- Aditi Milind Panandikar - Managing Director
- Suresh Govind Kare - Director
- Vasudha Vasant Kamat - Director
- Abhijit Yashawant Gore - Director
- Satish Madhav Shenoy - Director
- Ajay Prasan Mulgaokar - Director
The GSTIN of Indoco Remedies is 27AAACI0380C1Z3, registered in Maharashtra. The company has 28 GST registrations in all, of which 21 are active and 7 are cancelled or inactive. Other active GSTINs include 27AAACI0380C2Z2 (Maharashtra), 02AAACI0380C1ZF (Himachal Pradesh), 03AAACI0380C1ZD (Punjab).
The CIN (Corporate Identification Number) of Indoco Remedies is L85190MH1947PLC005913. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Indoco Remedies is listed on both BSE (code: 532612) and NSE (symbol: INDOCO).
Indoco Remedies has 224 court cases on record: 154 filed by the company and 71 filed against it. 47 are pending. Most are in the district courts.
Indoco Remedies was incorporated on 23 August 1947, making it 79+ years old. It is registered with the Registrar of Companies, Mumbai.
Indoco Remedies has 31 deals on record (27 market trades, 3 secondary share transfers, 1 funding round), with disclosed funding of ₹46.5 Lakh; the latest was in June 2026.
The peers of Indoco Remedies by revenue are Sai Life Sciences Limited, Leeford Healthcare Limited, MSN Pharmachem Private Limited, Bharat Biotech International Limited, La Renon Healthcare Private Limited and 5 more, all in the Pharma industry (API Manufacturers, Contract Research, Formulations).
Ajay Prasan Mulgaokar was appointed as Director on 01 Apr 2024. Satish Madhav Shenoy was appointed as Director on 01 Apr 2024. Divakar Madhusudan Gavaskar ceased to be Director on 31 Mar 2024. Indoco Remedies has 35 board changes on record in total.
Indoco Remedies has 19 MSME Form 1 returns on record between 2016 and 2024, listing 86 overdue payments to 45 micro and small suppliers. The latest return was filed on 01 May 2024.